Meeting of the Chronic Fatigue Syndrome Advisory Committee, 85980 [2016-28723]

Download as PDF 85980 Federal Register / Vol. 81, No. 229 / Tuesday, November 29, 2016 / Notices Shepherd at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: November 22, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016–28605 Filed 11–28–16; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Chronic Fatigue Syndrome Advisory Committee Office of the Assistant Secretary for Health, Department of Health and Human Services, Office of the Secretary. ACTION: Notice. AGENCY: As required by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that a meeting of the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will take place. This meeting will be open to the public. DATES: Thursday, January 12, 2017, from 12:00 p.m. to 5:00 p.m. ET, and Friday, January 13, 2017, from 9:00 a.m. to 5:00 p.m. ET. ADDRESSES: Individuals may attend this meeting in person and/or by utilizing virtual technology. Information for inperson attendance will be posted on the CFSAC Web site, http://www.hhs.gov/ ash/advisory-committees/cfsac/ meetings/index.html. Registration is required for in-person attendance. Information on the procedure to follow for registration will be included on the CFSAC Web site. For individuals wishing to attend the meeting virtually, a webinar will be offered. Information about accessing the webinar will be included on the CFSAC Web site. FOR FURTHER INFORMATION CONTACT: Gustavo Seinos, MPH, Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee, Department of Health and Human Services, 200 Independence Avenue SW., Room 712E, Washington, DC 20201. Please direct all inquiries to cfsac@hhs.gov. asabaliauskas on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:48 Nov 28, 2016 Jkt 241001 The CFSAC is authorized under 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended. The purpose of the CFSAC is to provide advice and recommendations to the Secretary of Health and Human Services, through the Assistant Secretary for Health on topics related to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The issues can include factors affecting access and care for persons with ME/CFS; the science and definition of ME/CFS; and broader public health, clinical, research, and educational issues related to ME/CFS. The agenda for this meeting, call-in information, and location will be posted on the CFSAC Web site http:// www.hhs.gov/ash/advisory-committees/ cfsac/meetings/index.html. Thirty minutes will be allotted for public comment via telephone or in person on each day of the meeting. Each individual will have three minutes to present their comments. Priority will be given to individuals who have not provided public comment within the previous year. We are unable to place international calls for public comments. Individuals are required to register to participate in the public comment sessions. To request a time slot for public comment, please send an email to cfsac@hhs.gov by January 5, 2017. The email should contain the speaker’s name and the telephone number at which the speaker can be reached for the public comment session. Individuals who would like for their testimony to be provided to the Committee members should submit a copy of the testimony prior to the meeting. It is preferred, but not required, that the submitted testimony be prepared in digital format and typed using a 12-pitch font. Copies of the written comment must not exceed 5 single-space pages, and it is preferred, but not required that the document be prepared in the MS Word format. Please note that PDF files, charts, and photographs cannot be accepted. Materials submitted should not include sensitive personal information, such as Social Security number, birthdate, driver’s license number, passport number, financial account number, or credit or debit card number. If you wish to remain anonymous, then document must specify this. The Committee welcomes input on any topic related to ME/CFS. SUPPLEMENTARY INFORMATION: Gustavo Seinos, Designated Federal Officer, CDR, USPHS. [FR Doc. 2016–28723 Filed 11–28–16; 8:45 am] BILLING CODE 4150–42–P PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing and Collaboration AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development. ADDRESSES: Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850–9702. FOR FURTHER INFORMATION CONTACT: Information on licensing and codevelopment research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850–9702, Tel. 240–276–5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Title of invention: Genetically Engineered Mouse-Derived Allograft for Use in Preclinical Studies of Metastatic Melanoma Therapies. Keywords: Melanoma, GDA, Allograft, Genetically Engineered Mouse, immunological response. Description of Technology: The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or codevelopment in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Before testing drugs in humans, drug developers are required to demonstrate a reasonable expectation of safety and efficacy by performing so-called preclinical studies. A key element of such trials is the use of animal models, SUMMARY: E:\FR\FM\29NON1.SGM 29NON1

Agencies

[Federal Register Volume 81, Number 229 (Tuesday, November 29, 2016)]
[Notices]
[Page 85980]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28723]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Chronic Fatigue Syndrome Advisory Committee

AGENCY: Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Office of the Secretary.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As required by the Federal Advisory Committee Act, the U.S. 
Department of Health and Human Services is hereby giving notice that a 
meeting of the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will 
take place. This meeting will be open to the public.

DATES: Thursday, January 12, 2017, from 12:00 p.m. to 5:00 p.m. ET, and 
Friday, January 13, 2017, from 9:00 a.m. to 5:00 p.m. ET.

ADDRESSES: Individuals may attend this meeting in person and/or by 
utilizing virtual technology. Information for in-person attendance will 
be posted on the CFSAC Web site, http://www.hhs.gov/ash/advisory-committees/cfsac/meetings/index.html. Registration is required for in-
person attendance. Information on the procedure to follow for 
registration will be included on the CFSAC Web site. For individuals 
wishing to attend the meeting virtually, a webinar will be offered. 
Information about accessing the webinar will be included on the CFSAC 
Web site.

FOR FURTHER INFORMATION CONTACT: Gustavo Seinos, MPH, Designated 
Federal Officer, Chronic Fatigue Syndrome Advisory Committee, 
Department of Health and Human Services, 200 Independence Avenue SW., 
Room 712E, Washington, DC 20201. Please direct all inquiries to 
cfsac@hhs.gov.

SUPPLEMENTARY INFORMATION: The CFSAC is authorized under 42 U.S.C. 
217a, Section 222 of the Public Health Service Act, as amended. The 
purpose of the CFSAC is to provide advice and recommendations to the 
Secretary of Health and Human Services, through the Assistant Secretary 
for Health on topics related to myalgic encephalomyelitis/chronic 
fatigue syndrome (ME/CFS). The issues can include factors affecting 
access and care for persons with ME/CFS; the science and definition of 
ME/CFS; and broader public health, clinical, research, and educational 
issues related to ME/CFS.
    The agenda for this meeting, call-in information, and location will 
be posted on the CFSAC Web site http://www.hhs.gov/ash/advisory-committees/cfsac/meetings/index.html.
    Thirty minutes will be allotted for public comment via telephone or 
in person on each day of the meeting. Each individual will have three 
minutes to present their comments. Priority will be given to 
individuals who have not provided public comment within the previous 
year. We are unable to place international calls for public comments. 
Individuals are required to register to participate in the public 
comment sessions. To request a time slot for public comment, please 
send an email to cfsac@hhs.gov by January 5, 2017. The email should 
contain the speaker's name and the telephone number at which the 
speaker can be reached for the public comment session.
    Individuals who would like for their testimony to be provided to 
the Committee members should submit a copy of the testimony prior to 
the meeting. It is preferred, but not required, that the submitted 
testimony be prepared in digital format and typed using a 12-pitch 
font. Copies of the written comment must not exceed 5 single-space 
pages, and it is preferred, but not required that the document be 
prepared in the MS Word format. Please note that PDF files, charts, and 
photographs cannot be accepted. Materials submitted should not include 
sensitive personal information, such as Social Security number, 
birthdate, driver's license number, passport number, financial account 
number, or credit or debit card number. If you wish to remain 
anonymous, then document must specify this.
    The Committee welcomes input on any topic related to ME/CFS.

Gustavo Seinos,
 Designated Federal Officer, CDR, USPHS.
[FR Doc. 2016-28723 Filed 11-28-16; 8:45 am]
 BILLING CODE 4150-42-P